Omnihealth Practice

CARDIOLOGY

Dapagliflozin as a treatment reduces worsening heart failure and cardiovascular death among heart failure patients

28 Feb 2021

Evolocumab greatly reduces low-density lipoprotein cholesterol levels in familial hypercholesterolemia: A local case review

30 Oct 2020

Prolonged use of DAPT with ticagrelor in a high-risk post-myocardial infarction patient: A local case report

01 Sep 2020

A case of patient with recurrent cardiovascular events stabilized by evolocumab in Hong Kong

29 Jun 2020

Evolocumab lowers lipoprotein(a) levels in triple-vessel coronary artery disease: A local case report

29 Apr 2020

A case review on cardiac risk stratification in the secondary prevention of cardiovascular diseases

28 Feb 2020

Self-care is the key in the management of chronic heart failure

31 Oct 2019

Overcoming the challenging journey: Secondary prevention of CV events with PCSK9i

30 Oct 2019

Self-care is the key in the management of chronic heart failure

Heart failure (HF) is a commonly occurring disease affecting numerous patients worldwide. The rates of new HF hospitalization among the Chinese population in Hong Kong between 2005 and 2012 were 0.59 in every 1,000 males and 0.58 in every 1,000 females.¹ Prognosis in relation to all-

31 Oct 2019

Dr. Chan, Wai-Kwong Andy

Specialist in Cardiology

ESC 2020

29 August - 1 September 2020 |

Virtual

Dapagliflozin as a treatment reduces worsening heart failure and cardiovascular death among heart failure patients

CARDIOLOGY

28 Feb 2021

Professor Yu, Cheuk-Man

Director of Heart Centre,
Hong Kong Baptist Hospital
Honorary Clinical Professor,
The Chinese University of Hong Kong

Evolocumab greatly reduces low-density lipoprotein cholesterol levels in familial hypercholesterolemia: A local case review

Patients with familial hypercholesterolemia (FH) have an elevated low-density lipoprotein cholesterol (LDL-C) level, which translates into a higher risk of cardiovascular events.¹ Although maximum standard treatment of statins and ezetimibe in FH patients helps reduce the LDL-C level by at

30 Oct 2020

Prof. Brian Tomlinson

Faculty of Medicine,
Macau University of Science and Technology

Previously considered safe low-dose glucocorticoids found to increase risk of cardiovascular diseases

Glucocorticoids are steroid hormones that have been widely adopted as the standard treatment for many inflammatory disorders.1 However, glucocorticoid receptors are expressed on almost all cell types in the body and their regulation by prolonged administration of glucocorticoids at high dose often p

28 Feb 2021

Sotagliflozin prevents cardiovascular events regardless of the left ventricular ejection fraction and presence of albuminuria

Type 2 diabetes mellitus (T2DM) is known to be associated with a 33% greater risk of hospitalization for heart failure (HF) and an increase in the risk of cardiovascular and overall death.1 Patients with coexisting T2DM and chronic kidney disease (CKD) are at further risk of HF and ischemic events t

28 Feb 2021

ONCOLOGY CARDIOLOGY NEUROLOGY RESPIROLOGY DIABETES & ENDOCRINOLOGY

Strategy to prevent and control NCDs in Hong Kong by 2025

30 Aug 2019